Compare Gilead Sciences, Inc. (GILD) vs Intel Corp (INTC) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

Intel (INTC) trades at $107.76, up 4.5% on the day, with a bearish technical signal but strong recent earnings beats. The company reported a net loss of -$267M for 2025, resulting in negative profit margins and ROE, while valuation ratios like a P/E of 904 appear extremely elevated. Positive sentiment is driven by news of progress with ASML's next-generation chipmaking technology and Jim Cramer's endorsement, with earnings due July 23.

The outlook is mixed: strategic manufacturing progress and AI ambitions offer long-term opportunity, but near-term fundamentals are weak with negative profitability. Key risks include intense semiconductor competition and execution on the capital-intensive foundry transition. Analyst consensus is a 'Hold' with a $107.55 price target, indicating the stock is fairly valued at current levels.